Company intelligence / Profile preview

iSTAR Medical

Ownership: Private
Employees: ~70
Development stage: Commercial

Overview

MINIject®, iSTAR Medical’s flagship minimally invasive glaucoma surgery device, has demonstrated significant and sustained intraocular pressure reduction over five years in the STAR-GLOBAL trial. Over 5,000 patients have been implanted globally. The device shows a strong safety and efficacy profile with long-term results supporting its use as a best-in-class solution for glaucoma management. It received CE Mark approval in Europe and continues to expand commercially while pursuing FDA approval in the US.

Therapeutic areas: Ophthalmology
Modalities: DeviceMinimally invasive implantOphthalmic implant
Industry: Implantable Medical Devices

Drug pipeline

1 asset

MINIject

Commercial

Indications: Glaucoma, Open-angle glaucoma

Partnerships

AbbVie (strategic partnership from July 2022 to April 2025; now ended)

Beyond the preview

Go deeper on iSTAR Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iSTAR Medical.

Explore the full profile